TY -的T1 -为什么双边丘脑下的刺激诱导帕金森症患者的认知能力下降?(S52.005) JF -神首页经学乔-神经病学SP - S52.005 LP - S52.005六世- 78 - 1补充非盟-中,大量非盟小薇吉妮Czernecki AU -迈克尔Schupbach盟他萨拉Fernandez-Vidal AU - Carine卡拉奇盟孤独纳瓦罗AU - Philippe角AU -伯纳德Pidoux AU - Luc锤盟迪迪埃Dormont AU -玛丽Vidailhet盟大卫Grabli AU - anne - Marie盖盟是被非盟- jean - Luc Houeto AU -埃里克Bardinet盟杰罗姆Yelnik AU -伊夫Agid Y1 - 2012/04/26 UR - //www.ez-admanager.com/content/78/1_Supplement/S52.005.abstract N2 -目的:理解为什么有些PD病人STN-HFS后今年开发了一个认知能力下降。背景STN-HFS是有效缓解帕金森运动迹象。然而,一些病人开发手术后认知功能的下降。设计/方法:在02/1996和07/2009,309 PD患者GHPS STN-HFS的操作。手术后患者评估之前和一年:1)神经心理学和精神测试,2)3)帕金森残疾量表(UPDRS部分我VI)。刺激接触得到的精确位置使用一个可调的三维图谱基底神经节。刺激参数和左旋多巴等效剂量被报道。voxel-based-morphometry也进行术前MRI的病人。Postoperative cognitive decline was defined as a decrease more than 1 SD in the MDRS one year after surgery and/or MDRS < 130. PD patients with vs without cognitive decline were compared with Student's t tests for continuous variables and Fisher's exact tests for categorical variables.Results: Two-hundred fifty-four patients were included in the final statistical analysis. Forty-five (21,5%) presented a decrease in the MDRS score more than 6 points (n=31) and/or a MDRS score under 130 (n=14). No statistical difference in the preoperative clinical characteristics was found between PD patients with vs without postoperative cognitive decline. Patients with postoperative cognitive decline presented a higher rate of postoperative confusion and/or psychiatric troubles. They showed a lower improvement in parkinsonian motor disability and activities of daily living with STN-HFS. The decrease in antiparkinsonian treatment and levodopa-induced complications was not different between the two patients groups. In patients with cognitive decline, the stimulating contacts were located more posteriorly and ventrally, and the frequency of stimulation was lower.Conclusions: STN-HFS may be deleterious for cognitive function, in particular when located in the more ventral part of the STN, thought to process cognitive and emotional information.Disclosure: Dr. Welter has nothing to disclose. Dr. Czernecki has nothing to disclose. Dr. Schupbach has received personal compensation for activities with Medtronic, Inc. and Lundbeck. Dr. Fernandez-Vidal has nothing to disclose. Dr. Karachi has nothing to disclose. Dr. Navarro has nothing to disclose. Dr. Cornu has nothing to disclose. Dr. Pidoux has nothing to disclose. Dr. Mallet has nothing to disclose. Dr. Dormont has nothing to disclose. Dr. Vidailhet has nothing to disclose. Dr. Grabli has nothing to disclose. Dr. Bonnet has nothing to disclose. Dr. Belaid has nothing to disclose. Dr. Houeto has nothing to disclose. Dr. Bardinet has nothing to disclose. Dr. Yelnik has nothing to disclose. Dr. Agid has nothing to disclose. Thursday, April 26 2012, 15:00 pm-16:30 pm ER -